Endpoints News· Ayisha Sharma·· 3 天前AI 评分72
ESMO26：Roche 公布 KRAS G12C 抑制剂在肺癌头对头试验中优于竞品的幅度
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
AI 导读
在 ESMO26 上，Roche 披露其新一代 KRAS G12C 抑制剂在经治突变非小细胞肺癌头对头试验中将死亡风险降低 44%。该报道正文需订阅后才能阅读完整内容。
正文 · 原文
MADRID — Roche’s next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news